Patients suspected of having coronary artery disease (CAD) who present with new onset chest pain can be investigated by numerous diagnostic modalities. National and international guidelines have been drawn up to assist cardiologists in selecting the most appropriate investigation(s). Here, we summarize and compare three current guidelines and discuss the differences between them.
The UK National Institute for Health and Care Excellence (NICE) published its guidelines in 2010. 1 The guidelines recommend that patients are categorized into 'low' or 'high' risk of CAD groups, depending on whether they have a cardiovascular risk factor (diabetes, smoking, and hyperlipidaemia). Patients are assigned a pre-test probability (PTP) score of having CAD based on risk category, age, gender, and typicality of chest pain. The guidance then suggests that patients with a PTP of ,10% should not be investigated further. Patients with a PTP of 10 -29% are recommended to undergo computed tomography (CT) calcium scoring. A zero calcium score is taken as confirmation of very low likelihood of CAD and no further testing is suggested. If the calcium score is above zero, it is recommended to proceed to a CT coronary angiogram (CTCA 
Discussion
There are important similarities and differences between the three guidelines. NICE and ESC have incorporated the Duke Clinical Score and a modified Diamond-Forrester Method PTP model, respectively, to select the appropriate investigation, whereas the ASC acknowledged the PTP models, but recommended the use of clinical judgment to define the likelihood of CAD. 5, 6 The PTP scores have consistently been shown to overestimate the likelihood of CAD, for example in the international registry, CONFIRM, in 14 048 patients who underwent CCTA. 7 In an attempt to reduce this overestimation, the ESC guidelines use the modified Diamond -Forrester Method which adjusts the likelihood of CAD for a more contemporary European patient population. 6 This is important in view of the lower prevalence of CAD, especially in primary care populations.
A further difference between the guidelines is the role of the exercise ECG. The ASC guideline recommends exercise ECG for patients with a low and intermediate likelihood of CAD. The ESC recommends exercise ECG in the same subgroup of patients, but only if there is limited local availability for functional imaging tests. NICE went further and recommended that the exercise ECG should no longer be used in the diagnosis of CAD. The rationale for NICE and ESC to move away from recommending the exercise ECG is its lower sensitivity and specificity, compared with imaging tests, that leads to a higher rate of second-line investigations, particularly ICA and thus higher follow on costs despite the lower upfront cost of the test. 8 Importantly, all three guidelines have introduced cardiac CT for the first time. The recommendation was limited to patients with low PTP in NICE and as an alternative to functional testing in patients with low and intermediate PTP in both ESC and ASC guidelines. The inclusion of cardiac CT in the guidelines reflects its emerging role as a highly effective rule out test, with an excellent negative predictive value (NPV). 9 However, the evidence for cardiac CT is still unfolding with major trials such as PROMISE, 10 which randomized 10 000 to CTCA or functional imaging tests, to report by the end of 2014. The use of CT calcium scoring in the NICE guidelines is motivated by its low cost and lower radiation exposure, combined with an excellent NPV, equivalent to the NPV of CTCA, in populations with low PTP, which was recently demonstrated in the CONFIRM registry. 11 The ESC, however, stated that the zero calcium score Editorial was not sufficiently accurate to rule out CAD. 3 As the radiation dose for CTCA on modern CT scanners continues to drop, it is often only marginally higher than for the calcium score, which may well be reflected in future guidelines. Finally, NICE attempted to limit the use of ICA, by limiting it to patients with a high PTP. However, this has been undermined by the mounting evidence that PTP models overestimate the incidence of CAD. 7 The ESC guidelines on the other hand recommend ICA for those with a positive functional imaging test and a high-event risk or those who fail medical therapy in the lower event risk groups, whereas the ASC guidelines recommend ICA for patients who have failed medical therapy. The trend in all three guidelines is to try to limit the use of diagnostic ICA. This is important as a recent large American registry demonstrated that only 37.6% of patients undergoing diagnostic ICA had obstructive CAD. 12 In summary, all three guidelines are based on a similar framework that takes into account the PTP and the diagnostic accuracy of the tests in the different PTP groups. The PTP models, including the modified Diamond -Forrester used by the ESC, 6 were derived from patient populations in tertiary settings with a high prevalence of CAD that overestimate the prevalence of CAD in primary care populations. In addition, there is a European trend to move towards more functional imaging tests for their superior accuracy compared with exercise ECG. The guidelines do not specify preferred functional imaging tests within population subsets, due to the lack of large comparative studies. The USA has traditionally used functional imaging tests, predominately MPS, much more widely, with huge cost implications and increased radiation burden to the population from multiple testing. 13 Hence, the ASC guidelines appear to be curbing the use of MPS by substituting it with exercise ECG. Studies comparing the outcomes of cardiac CT and functional imaging tests such as PROMISE and EVINCI will help clarify the optimal diagnostic test and will help refine future guidelines. 10, 14 For now the differences between the guidelines outlined above give cardiologists a degree of clinical freedom to choose the diagnostic tests based on local availability, local expertise, and local prevalence of CAD.
